Thermal Intravesical Chemotherapy Reduce Recurrence Rate for Non-muscle Invasive Bladder Cancer Patients: A Meta-Analysis

Liu, Kang; Jun, Zhu; Song, Yuxuan; Wang, Xiao; Zhou, Kexin; Lü, Yi; Liu, Xiaoqiang

doi:10.3389/fonc.2020.00029

Cited by 14 publications

(9 citation statements)

References 27 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…e effects of postoperative bladder intravesical chemotherapy: reducees recurrence rate, delays recurrence time, prevents infiltration and metastasis, improves survival rate, prolongs survival time, and improves quality of life [12]. Studies have shown that bladder intravesical chemotherapy can significantly reduce the recurrence rate of non-muscleinvasive bladder cancer after surgery [13][14][15]. e size of the drug dose, the frequency of treatment, and the length of the treatment course all have relative effects on the clinical effect.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence

Zhang

Chen

et al. 2021

Journal of Healthcare Engineering

View full text Add to dashboard Cite

Epirubicin, gemcitabine, and pirarubicin are widely used as first-line drugs for intravesical chemotherapy to prevent tumor recurrence after transurethral bladder tumor resection for non-muscle-invasive bladder cancer (NMIBC). However, which drug is better is less discussed. A total of 335 NMIBC patients administered intravesical chemotherapy underwent transurethral bladder tumor resection (TURBT) in our hospital from October 2015 to October 2019. After TURBT, all the patients received standard intravesical chemotherapy. Through clinical data collection and telephone follow-up, the tumor recurrence and adverse reactions of all patients after bladder perfusion treatment were counted. Recurrence was defined as new tumor appearance in the bladder. Of the 335 patients who underwent intravesical chemotherapy, 109 patients received epirubicin and 114 patients and 112 patients were given gemcitabine and pirarubicin, respectively. According to the general information of the patients, the patients were divided into intermediate-risk and high-risk bladder cancer and compared separately. There was no statistical difference in clinical and pathological features between different groups ( P > 0.05 ). The recurrence rate of intermediate-risk bladder cancer patients shows no difference between three groups ( P > 0.05 ). As for the high-risk bladder cancer patients, it is found that the 1-year recurrence rate between three groups was not statistically significant ( P > 0.05 ), whereas the 2-year recurrence rate of patients given gemcitabine (9.87%) was significantly lower than that of epirubicin (25.37%) and pirarubicin (24.32%), and the difference was statistically significant ( P < 0.017 , Bonferroni adjusted P value). The Kaplan–Meier survival curves showed that the recurrence-free survival rate of patients received gemcitabine was significantly higher than that of the other two groups. Comparing the incidence of adverse reactions during the infusion of the three groups of patients, the differences were not statistically significant ( P > 0.05 ). In patients with high-risk non-muscle-invasive bladder cancer, the application of gemcitabine intravesical chemotherapy is related with a relatively lower recurrence rate but similar incidence of adverse reactions.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence

Zhang

Chen

et al. 2021

Journal of Healthcare Engineering

View full text Add to dashboard Cite

show abstract

“… 121 , 123 , 124 It involves the intravesical application of heated chemotherapy to the bladder through use of microwaves to heat the local bladder environment or through circulation of heated fluids (hyperthermic intravesical chemotherapy [HIVEC]). 121 , 122 , 125 , 126 In a meta-analysis of 12 studies, intravesical chemothermotherapy was associated with a significantly decreased risk of disease recurrence compared with normal-temperature chemotherapy after 2 years, with no difference in the rate of AEs. 125 However, AEs of hematuria, bladder spasms, and pain have been reported with chemothermotherapy.…”

Section: Discussionmentioning

confidence: 99%

“… 121 , 122 , 125 , 126 In a meta-analysis of 12 studies, intravesical chemothermotherapy was associated with a significantly decreased risk of disease recurrence compared with normal-temperature chemotherapy after 2 years, with no difference in the rate of AEs. 125 However, AEs of hematuria, bladder spasms, and pain have been reported with chemothermotherapy. 122 , 127 While no studies on chemothermotherapy were identified in our SLR, it is a treatment option that should be considered by the treating physician.…”

Section: Discussionmentioning

confidence: 99%

<p>Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews</p>

Lee¹,

Kwon²,

Forsythe³

et al. 2020

CEOR

View full text Add to dashboard Cite

Purpose: Non-muscle invasive bladder cancer (NMIBC) is a malignancy restricted to the inner lining of the bladder. Intravesical Bacillus Calmette-Guerin (BCG) following transurethral resection of the bladder tumor is the mainstay first-line treatment for high-risk NMIBC patients. Two systematic literature reviews (SLRs) were conducted to further assess the current evidence on BCG use in NMIBC and the humanistic and economic burden of disease. Methods: Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, Embase ® and MEDLINE ® were searched using the Ovid platform to identify interventional or real-world evidence studies on the health-related quality of life (HRQoL) and economic burden in NMIBC. Limited evidence was found from initial economic SLR searches in NMIBC, so additional targeted searches for bladder cancer were conducted to expand findings. Results: Fifty-nine publications were included in the HRQoL SLR, of which 23 reported HRQoL and symptoms in NMIBC. At diagnosis, HRQoL was comparable with population norms but worsened considerably 2 years following diagnosis. Maintenance therapy with intravesical BCG was associated with reduced HRQoL, and treatment-related adverse events (AEs) resembled typical NMIBC symptoms. Twenty-two studies reported decreasing BCG compliance over time. Common AEs with BCG were frequent urination, lower urinary tract symptoms, pain, and hematuria. Forty-two publications were included in the economic SLR, of which nine assessed healthcare costs and resource use in NMIBC or bladder cancer. Highrisk disease and high-intensity treatment were associated with increased healthcare costs. Conclusion: NMIBC has a considerable symptomatic, HRQoL, and economic burden. Symptoms persisted and HRQoL worsened despite intravesical BCG treatment. NMIBC is a costly disease, with higher healthcare costs associated with increased risk of disease progression and recurrence. There is a high unmet need for safe and effective treatments that reduce the risk of disease progression and recurrence, provide symptomatic relief, and improve HRQoL for patients.

show abstract

“…Compared to normal temperature chemotherapy, there was a significantly lower recurrence rate with the use of thermal chemotherapy at 2-year follow-up (RR= 0.3, 95% CI: 0.21-0.43). Adverse events did not significantly differ between the two groups, making this a viable option [54,55]. The analysis, however, was limited by the heterogeneity of chemotherapeutic agents and protocols utilized as well as varied risk levels amongst the study participants, which may bias direct comparisons.…”

Section: Novel Modes Of Drug Deliverymentioning

confidence: 99%

Pharmacologic Therapies for Non-Muscle Invasive Bladder Cancer: Current and Future Treatments

Goldberg

Lichtbroun

Singer

et al. 2022

Arch Pharmacol Ther

View full text Add to dashboard Cite

We performed a narrative review using PubMed, Google Scholar, Clinical Key, and Wiley Online Library of articles between the years of 1980 and 2021. Search terms included combinations of terms such as "non-muscle invasive bladder cancer, " "guidelines, " "pharmacotherapy, " "salvage therapy, " and "immunotherapies. " Only original articles published in English were included. Editorials and media articles were not included.For clinical trial information, we searched www.clinicaltrials. gov. This was accessed in September of 2021. We included Phase II-IV trials. This is not a comprehensive list of all trials for NMIBC. The search terms: "non-muscle invasive bladder

show abstract

Thermal Intravesical Chemotherapy Reduce Recurrence Rate for Non-muscle Invasive Bladder Cancer Patients: A Meta-Analysis

Cited by 14 publications

References 27 publications

Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence

Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence

<p>Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews</p>

Pharmacologic Therapies for Non-Muscle Invasive Bladder Cancer: Current and Future Treatments

Contact Info

Product

Resources

About